Our CSO, Keiichi Nakayama, spoke at Investor Day Japan 2026. Click here to view highlights from the event.
2026.02.24
News
Our CSO, Keiichi Nakayama, will be presenting at Investor Day Japan 2026. Click here for more details.
2026.01.27
News
We have compiled a list of our selected R&D projects. View the full list here.
2025.12.19
News
We are pleased to announce that our CSO, Keiichi Nakayama, has received the Uehara Prize. Click here for more details.
2025.12.09
News
Thank you to everyone who attended our CSO Keiichi Nakayama's pitch at ILS 2025 and visited our booth. We appreciate your interest and look forward to sharing our future progress.
2025.11.12
News
Our CSO, Keiichi Nakayama, will be speaking at the ILS 2025 Startup Pitch.
Click here for more details about the presentation.
2025.10.31
News
Our R&D project, "Preclinical Study of Innovative Metabolic Inhibitors Targeting Refractory Cancers," has been selected for AMED's Program for Innovative Cancer Therapy Development. Read more here.
2025.10.29
News
Our R&D project, "Identification and Development of Therapeutics for Cancer Stem Cells Using Non-Destructive Omics," has been selected for funding under AMED's FY2025 Research Project for Accelerating Next-Generation Cancer Treatment. Click here for more details.
2025.09.24
News
We are developing inhibitors targeting three molecules involved in cancer cell proliferation and survival. Learn more about our pipeline here.
2025.08.01
News
Our CEO, Teruyasu Nishino, spoke at the "International Open Innovation & Startup Symposium 2025" held on Wednesday, July 23, hosted by the Institute of Science Tokyo. View the event highlights here.
2025.07.18
News
Our CEO, Teruyasu Nishino, will be speaking at the "International Open Innovation & Startup Symposium 2025," hosted by the Institute of Science Tokyo, on Wednesday, July 23. We look forward to seeing you there. Click here for more details.
2025.06.24
News
Our website has been updated with detailed information about our pipeline programs. Explore the new content here.
2025.05.28
News
AntiCancer Technologies Inc. has launched its official social media accounts to better share company news and updates. We will continue to keep you informed about our latest activities and announcements. Facebook, LinkedIn, X, and Instagram
2025.04.25
News
We have been selected for the NCC Seed Acceleration Program (NCC SAP), a startup support program hosted by the Center for Promotion of Translational Research at the National Cancer Center Japan. Learn more here.
2025.04.11
News
We have published research results obtained through the development of cancer immunotherapy and molecular targeted drugs in multiple peer-reviewed academic journals. A list of papers published since 2011 is available here.
2024.10.07
News
AntiCancer Technologies Inc. has been selected for the 11th cohort of "1stRound," Japan's largest academia-supported startup acceleration program organized by UTokyo IPC.(article here)
2024.06.15
News
The achievements of the Nakayama Laboratory will be broadcast on BS TV Tokyo "Ima kara Science" (from 10 PM on Wednesday, June 19) (Click here for preview)
2024.06.11
News
AntiCancer Technologies Inc. (Chiyoda-ku, Tokyo) conducted a third-party allotment capital increase with multiple angel investors as underwriters.
2024.06.07
News
An introduction to AntiCancer Technologies Inc. was featured in Nikkei Biotech's "Venture Exploration" (Click here for the article)
2024.05.01
News
Official website launched.
2024.02.21
News
Certified as a Startup of Tokyo Medical and Dental University.
2023.10.24
News
Filed a basic patent application for Pipeline 1.
2023.10.23
News
Our CSO, Keiichi Nakayama, had a discussion with Mr. Takafumi Horie (See link)